Key result
Low HDL-C and HDL dysfunction are linked to chronic kidney disease development and progression.
Answers are grounded in this paper and cite their sources.
Low HDL-cholesterol (HDL-C) concentrations are a typical trait of the dyslipidemia associated with chronic kidney disease (CKD). In this condition, plasma HDLs are characterized by alterations in structure and function, and these particles can lose their atheroprotective functions, e.g., the ability to promote cholesterol efflux from peripheral cells, anti-oxidant and anti-inflammatory proprieties and they can even become dysfunctional, i.e., exactly damaging. The reduction in plasma HDL-C levels appears to be the only lipid alteration clearly linked to the progression of renal disease in CKD patients. The association between the HDL system and CKD development and progression is also supported by the presence of genetic kidney alterations linked to HDL metabolism, including mutations in the APOA1, APOE, APOL and LCAT genes. Among these, renal disease associated with LCAT deficiency is well characterized and lipid abnormalities detected in LCAT deficiency carriers mirror the ones observed in CKD patients, being present also in acquired LCAT deficiency. This review summarizes the major alterations in HDL structure and function in CKD and how genetic alterations in HDL metabolism can be linked to kidney dysfunction. Finally, the possibility of targeting the HDL system as possible strategy to slow CKD progression is reviewed.
No takes yet. Share an insight, caveat, or question.
Pavanello et al. (2023) conducted a review in Chronic kidney disease (CKD). HDL-cholesterol structure, function, and genetic metabolism alterations was evaluated. Low HDL-C and alterations in HDL structure, function, and metabolism (including LCAT deficiency) are linked to the development and progression of chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: